- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02120482
Combined Apheresis for ABO-incompatible Transplantation - a Pilot Study
Semiselective Immunoadsorption and Membrane Filtration for Desensitization in ABO-incompatible Kidney Transplantation - a Phase 2 Pilot Study
Study Overview
Status
Intervention / Treatment
Detailed Description
-Background and study aims
ABO-incompatible living donor kidney transplantation (ABOi-KTX) offers the possibility to expand the donor pool by approximately 30%. A variety of different desensitization protocols were shown to enable successful transplantation across major ABO barriers. In this context, apheresis for antibody depletion represents the therapeutic mainstay. Two distinct technical principles, plasmapheresis and ABO antigen-specific immunoadsorption, were shown to allow for excellent short- and intermediate-term outcomes. A particular technical advantage of immunoadsorption may be its high selectivity regarding antibody depletion, which precludes major losses of essential plasma constituents, including coagulation factors and albumin, even after treatment of large plasma volumes. Nevertheless, high treatment costs associated with the use of ABO-specific columns (that are not approved for reuse) and may limit their widespread clinical application.
The efficiency of semi-selective immunoadsorption technologies regarding ABO antibody depletion and recipient desensitization is less well established. Theoretically, non-antigen-specific immunoglobulin depletion using protein A-, GAM peptide-, or anti-Ig antibody-based adsorbers, could bring about several advantages, such as lower treatment costs associated with the use of reusable twin columns, and the potential to simultaneously deplete antibodies also against HLA antigens. In a randomized controlled crossover study including patients with autoimmune disease, we could demonstrate that the combination of semi-selective immunoadsorption together with membrane filtration can efficiently deplete both ABO-specific IgM and IgG and also has a significant impact on complement levels and functionality (Eskandary et al. 2014, Nephrology Dialysis Transplantation; www.clinicaltrials.gov, NCT01698736). In this non-randomized, open, uncontrolled phase II multi center (N=10) pilot study, we will investigate whether our novel concept of combined apheresis can be safely and efficiently applied in the context of ABOi-KTX.
- Recipient desensitization
Four weeks before scheduled transplantation, patients will receive CD20 antibody rituximab (357mg/m2). Two weeks before ABOi-KTX baseline triple immunosuppression with tacrolimus (trough level 12-15 ng/mL), mycophenolate-mofetil (2g daily) and steroids (25mg daily) will be started. IL-2 receptor antibody basiliximab (20 mg) will be administered directly before and four days after KTX. Combined apheresis treatments (6-9) will be started 1-2 weeks before transplantation (One week if initial ABO-antibody titers are below 1:512, two weeks if initial ABO-antibody titers are ≥1:512). Instead of ABO-specific immunoadsorption columns (Glycosorb® AB-columns, Glycorex®, Lund, Sweden) we will use GAM-146 synthetic peptide columns (Globaffin®, Fresenius Medical Care, Bad Homburg, Germany). To optimize antibody and complement elimination a membrane filter will be connected to the circuit (MONET®, Fresenius Medical Care, Bad Homburg, Germany) during every second treatment [targeted pre-transplant antibody titers: <1:16 (IgG); <1:8 (IgM)].
Whenever reaching target titers is not possible, the treatment can be pursued by using antigen-specific immunoadsorption (Five to nine serial treatments including one immediately pre-transplant). If this treatment also fails to reach sufficiently low antibody titers, transplantation will not be carried out. In case of hypofibrinogenemia (<100 mg/dL) 2-4 units of fresh frozen plasma (pooled or single donor) will be administered.
- Post transplantation management
Postoperative management will adhere to center standard. ABO-antibody titers will be determined thrice weekly during the first weeks post KTX, after four weeks, three months and after six months. On-demand combined apheresis will only be performed if postoperative titers rise to >1:16 during the first week or >1:32 during the second week post KTX, or in case of an antibody-mediated rejection. A protocol biopsy will be performed on the 7th-10th day after transplantation. Prophylactic treatment with valacyclovir and trimethoprim/sulfamethoxazole will be carried out for six months. Patients will be regularly seen in our outpatient clinic according to center standard.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Division of Medicine III, Dpt. of Nephrology and Dialysis, Medical University Vienna
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Eligibility for living donor ABO-incompatible kidney transplantation according to center standard
- Age >18 years
- Signed written informed consent
- Negative cytotoxic and flow-cytometric crossmatch
Exclusion Criteria:
- Age<18 years
- No signed written informed consent
- Blood group AB (no isoagglutinins)
- Pregnant and breastfeeding women
- HLA-sensitized patients (i.e. patients with preformed antibodies against donor HLA antigens)
- Positive cytotoxic and flow-cytometric crossmatch
- Severe blood coagulation disorder precluding the use of membrane filtration or immunoadsorption
- Initial serum fibrinogen <200mg/dL
- IgA deficiency
- Any severe disease (e.g. severe infection) precluding ABOi-KTX
- Heparin intolerance
- Polysulfone intolerance
- Participation in any other intervention trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combined apheresis
Patients will be treated by semiselective immunoadsorption combined with membrane filtration
|
Semiselective immunoadsorption combined with membrane filtration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidence of antibody-mediated rejection (AMR) within three months after transplantation
Time Frame: First three months after transplantation
|
Antibody-mediated rejection according to Banff 2013 criteria
|
First three months after transplantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Successful desensitization for ABOi transplantation
Time Frame: Day of transplantation
|
Reduction of ABO antigen-specific IgG titers to <1:16 and IgM titers to <1:8
|
Day of transplantation
|
Kidney function
Time Frame: First six months after transplantation
|
Evaluation of estimated GFR and serum creatinine trajectories
|
First six months after transplantation
|
Rate of cellular rejection
Time Frame: First six months after transplantation
|
The incidence of cellular rejection according to Banff 2011 histological classification
|
First six months after transplantation
|
Graft survival
Time Frame: First six months after transplantation
|
Graft loss will be determined as the need for permanent dialysis
|
First six months after transplantation
|
Patient survival
Time Frame: First six months after transplantation
|
Patient death within the first six months will be documented
|
First six months after transplantation
|
Reduction in flow-cytometric ABO-specific IgM
Time Frame: Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
The efficacy of percent ABO-specific IgM reduction will be assessed at baseline and before and after each apheresis treatment and post transplantation.
|
Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
Reduction in flow-cytometric ABO-specific IgG
Time Frame: Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
The efficacy of percent ABO-specific IgG reduction will be assessed at baseline and before and after each apheresis treatment and post transplantation.
|
Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
Reduction in flow-cytometric ABO-specific IgG subclass III
Time Frame: Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
The efficacy of percent ABO-specific IgG subclass III reduction will be assessed at baseline and before and after each apheresis treatment and post transplantation.
|
Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
Reduction in ABO-specific IgM antibody titers
Time Frame: Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
The efficacy of ABO-specific IgM titer reduction will be assessed at baseline and before and after each apheresis treatment and post transplantation.
|
Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
Reduction in ABO-specific IgG antibody titers
Time Frame: Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
The efficacy of ABO-specific IgG titer reduction will be assessed at baseline and before and after each apheresis treatment and post transplantation.
|
Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
Reduction in serum IgM
Time Frame: Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
The efficacy of serum IgM reduction will be assessed at baseline and before and after each apheresis treatment and post transplantation.
|
Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
Reduction in serum IgG
Time Frame: Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
The efficacy of serum IgG reduction will be assessed at baseline and before and after each apheresis treatment and post transplantation.
|
Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
Reduction of serum IgG subclasses I-IV
Time Frame: Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
The efficacy of serum IgG subclass I-IV reduction will be assessed at baseline and before and after each apheresis treatment and post transplantation.
|
Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
Reduction of classical complement key component C1q
Time Frame: Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
The efficacy of serum C1q reduction will be assessed at baseline and before and after each apheresis treatment and post transplantation.
|
Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
Reduction of complement component C3
Time Frame: Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
The efficacy of serum C3 reduction will be assessed at baseline and before and after each apheresis treatment and post transplantation.
|
Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
Reduction of complement component C4
Time Frame: Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
The efficacy of serum C4 reduction will be assessed at baseline and before and after each apheresis treatment and post transplantation.
|
Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
Reduction in complement functionality assessed by CH50 activity
Time Frame: Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
The efficacy of CH50 activity reduction will be assessed at baseline and before and after each apheresis treatment and post transplantation.
|
Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
Reduction of classical complement functionality assessed by Luminex HLA-single bead assay technology
Time Frame: Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
The efficacy of the reduction in classical complement functionality will be assessed at baseline and before and after each apheresis treatment and post transplantation.
|
Pre and post apheresis treatment and 1, 2, 4 weeks and 3 and 6 months post transplantation
|
Delayed graft function
Time Frame: First week post transplantation
|
The incidence of delayed graft function will be assessed as the rate of patients with the need for dialysis during the first week post transplantation
|
First week post transplantation
|
Surgical complications
Time Frame: First month after transplantation
|
Incidence of surgical complications, such as bleeding, arterial/venous graft thrombosis, will be assessed during the first month post transplantation
|
First month after transplantation
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Georg A Böhmig, MD, Medical University Vienna, Division of Medicine III, Dpt. of Nephrology and Dialysis
Publications and helpful links
General Publications
- Eskandary F, Wahrmann M, Biesenbach P, Sandurkov C, Konig F, Schwaiger E, Perkmann T, Kunig S, Derfler K, Zlabinger GJ, Bohmig GA. ABO antibody and complement depletion by immunoadsorption combined with membrane filtration--a randomized, controlled, cross-over trial. Nephrol Dial Transplant. 2014 Mar;29(3):706-14. doi: 10.1093/ndt/gft502. Epub 2013 Dec 29.
- Wahrmann M, Schiemann M, Marinova L, Kormoczi GF, Derfler K, Fehr T, Stussi G, Bohmig GA. Anti-A/B antibody depletion by semiselective versus ABO blood group-specific immunoadsorption. Nephrol Dial Transplant. 2012 May;27(5):2122-9. doi: 10.1093/ndt/gfr610. Epub 2011 Nov 15.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- EK2123/2013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antibody-mediated Rejection
-
Brigham and Women's HospitalAlexion PharmaceuticalsTerminatedAntibody-mediated Rejection | Humoral RejectionUnited States
-
Shahid Beheshti University of Medical SciencesRecruitingAntibody-mediated RejectionIran, Islamic Republic of
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruitingAntibody-mediated RejectionChina
-
Farsad EskandaryCharite University, Berlin, Germany; University of Alberta; HI-BioCompleted
-
CSL BehringTerminatedAntibody-mediated RejectionUnited States, Spain, France, Netherlands, United Kingdom, Belgium, Germany
-
Medical University of ViennaCharite University, Berlin, Germany; University of Alberta; CSL BehringCompleted
-
University of ManitobaTerminatedAntibody Mediated RejectionCanada
-
Thomas MuellerUnknownAntibody-mediated Rejection
-
Medical University of ViennaRecruitingLung Transplant Rejection | Antibody-mediated RejectionAustria
-
University Hospital, MontpellierInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedAntibody-mediated RejectionFrance
Clinical Trials on Combined apheresis
-
Karl WinklerCompletedHypertension | Proteinuria | Dyslipidemia | PreeclampsiaGermany
-
Emory UniversityKaneka Medical America LLCCompletedFamilial HypercholesterolemiaUnited States
-
Laval UniversityCompleted
-
Imperial College LondonNational Institute for Health Research, United KingdomCompletedRefractory Angina | Raised Lipoprotein(a)>50mg/dL or >500mg/LUnited Kingdom
-
Otsuka Frankfurt Research Institute GmbHCompletedUlcerative Colitis
-
University of PaviaIRCCS Policlinico S. MatteoWithdrawn
-
Otsuka America PharmaceuticalCompletedUlcerative ColitisUnited States, Canada
-
Otsuka Frankfurt Research Institute GmbHCompleted
-
Fresenius Medical Care Deutschland GmbHCompletedCardiovascular Diseases | Dyslipidemias | Hypercholesterolemia, FamilialGermany
-
Charite University, Berlin, GermanyNeuroCure Clinical Research Center, Charite, Berlin; Department of Nephrology...Recruiting